LaPlant BR - Search Results

1

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA. Ballman KV, et al. Among authors: laplant br. Neuro Oncol. 2007 Jan;9(1):29-38. doi: 10.1215/15228517-2006-025. Epub 2006 Nov 15. Neuro Oncol. 2007. PMID: 17108063 Free PMC article. Clinical Trial.

2

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM; North Central Cancer Treatment Group. Roy V, et al. Among authors: laplant br. Ann Oncol. 2009 Mar;20(3):449-53. doi: 10.1093/annonc/mdn661. Epub 2008 Dec 15. Ann Oncol. 2009. PMID: 19087987 Free PMC article. Clinical Trial.

3

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, LaPlant B, Laumann K, Erlichman C, DiPersio J. Cashen A, et al. Ann Hematol. 2012 Jan;91(1):33-8. doi: 10.1007/s00277-011-1240-1. Epub 2011 May 3. Ann Hematol. 2012. PMID: 21538061 Free PMC article. Clinical Trial.

4

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE. Nowakowski GS, et al. J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18. J Clin Oncol. 2015. PMID: 25135992 Clinical Trial.

5

A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

Mattison R, Jumonville A, Flynn PJ, Moreno-Aspitia A, Erlichman C, LaPlant B, Juckett MB. Mattison R, et al. Leuk Lymphoma. 2015 Jul;56(7):2061-6. doi: 10.3109/10428194.2014.977886. Epub 2014 Nov 19. Leuk Lymphoma. 2015. PMID: 25329007 Free PMC article. Clinical Trial.

6

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.

Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Kumar SK, et al. Blood Cancer J. 2015 Aug 14;5(8):e338. doi: 10.1038/bcj.2015.60. Blood Cancer J. 2015. PMID: 26275080 Free PMC article. Clinical Trial.

7

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

Crozier JA, Advani PP, LaPlant B, Hobday T, Jaslowski AJ, Moreno-Aspitia A, Perez EA. Crozier JA, et al. Clin Breast Cancer. 2016 Feb;16(1):23-30. doi: 10.1016/j.clbc.2015.08.002. Epub 2015 Aug 19. Clin Breast Cancer. 2016. PMID: 26381420 Free PMC article. Clinical Trial.

8

Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.

Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Strati P, et al. Among authors: laplant br. Lancet Haematol. 2016 Sep;3(9):e407-14. doi: 10.1016/S2352-3026(16)30064-3. Epub 2016 Aug 1. Lancet Haematol. 2016. PMID: 27570087 Clinical Trial.

9

Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.

Kay NE, LaPlant BR, Pettinger AM, Call TG, Leis JF, Ding W, Parikh SA, Conte MJ, Bowen DA, Shanafelt TD. Kay NE, et al. Among authors: laplant br. Expert Rev Hematol. 2018 Apr;11(4):337-349. doi: 10.1080/17474086.2018.1442716. Epub 2018 Feb 26. Expert Rev Hematol. 2018. PMID: 29460654 Clinical Trial.

10

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).

Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ. Yin J, et al. Blood Adv. 2019 Jun 11;3(11):1714-1721. doi: 10.1182/bloodadvances.2018026112. Blood Adv. 2019. PMID: 31171508 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page